Artivion (NYSE:AORT) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Key Points

• Artivion reported Q1 EPS of $0.08, beating estimates by $0.02, and showed operational leverage with revenue +12% (constant currency) and adjusted EBITDA up 26% to $22.1M (19% margin), while net leverage fell to 1.8x.
• Management exercised its option to acquire Endospan after FDA PMA of the NEXUS device, expects the deal to close in Q2 2026 funded by a $150M term‑loan (to pay a $135M upfront), with a U.S. commercial launch planned for January 1, 2027.
• The company trimmed 2026 guidance to 7%–11% adjusted constant‑currency revenue growth ($480M–$496M) and adjusted EBITDA of $100M–$107M (or $92M–$99M including ~ $8M incremental Endospan costs), citing softer stent graft sales and timing of AMDS starter‑set orders.

Artivion (NYSE:AORT - Get Free Report) released its earnings results on Thursday. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02, Zacks reports. Artivion had a net margin of 2.21% and a return on equity of 7.43%.

Here are the key takeaways from Artivion's conference call:

• Artivion exercised its option to acquire Endospan after FDA PMA of the NEXUS aortic arch stent graft, expects close in Q2 2026, funded by a $150M term‑loan draw to pay the $135M upfront, and plans a U.S. commercial launch on January 1, 2027 with NEXUS positioned as a platform supported by three additional PMA programs.
• The company trimmed full‑year 2026 guidance to 7%–11% adjusted constant‑currency revenue growth ($480M–$496M) and now expects adjusted EBITDA of $100M–$107M (or $92M–$99M including an estimated $8M of incremental Endospan‑related expenses), citing softer stent graft sales and timing of AMDS starter set orders.
• AMDS implant and reorder rates outperformed expectations, but initial "starter set" sales lag because hospitals face a ~$100k upfront stocking cost and some are deferring until anticipated mid‑2026 PMA/IRB simplification; management expects set sales to accelerate after PMA and via programs to ease the upfront burden.
• Q1 performance showed operational leverage: total revenue +12% (constant currency), adjusted EBITDA +26% to $22.1M with a 19% margin (≈130 bps improvement), improved gross margin (64.9%), better free cash flow versus prior year, and net leverage reduced to 1.8x from 4.0x.

Artivion Trading Up 1.9%

Artivion stock traded up $0.65 during trading hours on Thursday, reaching $35.38. The stock had a trading volume of 897,221 shares, compared to its average volume of 407,773. The stock has a market cap of $1.72 billion, a PE ratio of 176.93 and a beta of 1.41. Artivion has a 52 week low of $28.07 and a 52 week high of $48.25. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62. The company has a fifty day simple moving average of $36.50 and a 200-day simple moving average of $41.19.

Analyst Ratings Changes

AORT has been the topic of several recent research reports. Stifel Nicolaus set a $55.00 target price on shares of Artivion in a report on Thursday, March 5th. Canaccord Genuity Group cut their price target on shares of Artivion from $51.00 to $48.00 and set a "buy" rating on the stock in a report on Friday, February 13th. LADENBURG THALM/SH SH raised shares of Artivion from a "neutral" rating to a "buy" rating and set a $42.00 price target on the stock in a report on Friday, April 10th. Needham & Company LLC reissued a "buy" rating on shares of Artivion in a report on Monday, April 20th. Finally, Weiss Ratings raised shares of Artivion from a "sell (d)" rating to a "hold (c-)" rating in a report on Friday, February 20th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $51.00.

Insiders Place Their Bets

In other news, CAO Amy Horton sold 901 shares of the firm's stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $34,039.78. Following the completion of the sale, the chief accounting officer directly owned 139,088 shares of the company's stock, valued at approximately $5,254,744.64. This trade represents a 0.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Jean F. Holloway sold 8,962 shares of the firm's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $38.00, for a total transaction of $340,556.00. Following the completion of the sale, the senior vice president directly owned 185,095 shares of the company's stock, valued at approximately $7,033,610. This represents a 4.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 133,043 shares of company stock worth $4,977,158. 6.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Artivion

Several institutional investors and hedge funds have recently modified their holdings of the stock. Invesco Ltd. lifted its position in shares of Artivion by 211.9% in the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company's stock worth $50,228,000 after purchasing an additional 748,119 shares during the period. XTX Topco Ltd purchased a new stake in shares of Artivion in the 4th quarter worth about $746,000. Susquehanna Portfolio Strategies LLC lifted its position in shares of Artivion by 21.5% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 40,542 shares of the company's stock worth $1,849,000 after purchasing an additional 7,186 shares during the period. Occudo Quantitative Strategies LP purchased a new stake in shares of Artivion in the 4th quarter worth about $248,000. Finally, Millennium Management LLC lifted its position in shares of Artivion by 1.0% in the 4th quarter. Millennium Management LLC now owns 91,816 shares of the company's stock worth $4,188,000 after purchasing an additional 893 shares during the period. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc NYSE: AORT is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.